



CryoLife Stock Ranked Among the 100 Best Stocks to Own for Under \$20

June 30, 1999

Business Editors/Health and Medical Writers

ATLANTA--(BUSINESS WIRE)--June 30, 1999--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that its stock has been ranked 38th among The 100 Best Stocks to Own for Under \$20 in a book published by Gene Walden, nationally known stock market expert, analyst and author of The 100 Best Stocks to Own in America. The 100 stocks on the list, which were chosen from Mr. Walden's evaluation of 6,000 small stocks, were evaluated using a 16-point rating system based on their four-year earnings growth, four-year revenue growth, three-year stock growth, and four-year consistency of earnings and revenue.

Steven G. Anderson, President and Chief Executive Officer of CryoLife, said, "We are pleased that our success is receiving national attention, and we are indeed honored to be included in this distinguished list. This ranking demonstrates our commitment to add value for our shareholders in critical areas such as profitability, margin growth and sales, while continuing to focus on our goal of developing new technology to address the growing needs of the medical community, including the need for viable living human tissue for transplantation and innovations in heart valves and surgical adhesives."

Founded in 1984, CryoLife, Inc. is the leader in the development and commercialization of implantable living human tissues for use in cardiovascular, vascular, and orthopaedic surgeries throughout the United States and Canada. The Company's BioGlue(R) surgical adhesive, CE marked in the European Union for use in vascular and pulmonary sealing and repair, is distributed throughout Europe. The Company also manufactures CryoLife-O'Brien(R) and CryoLife-Ross(TM) stentless porcine heart valves which are distributed within the European Community.

Statements made in this press release which look forward in time involve risks and uncertainties and are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such risks and uncertainties include changes in economic cycles, competition from other companies, changes in laws and governmental regulations applicable to the Company and other risk factors detailed in the Company's Securities and Exchange Commission filings, including the Company's Prospectus dated March 30, 1998, contained in its Registration Statement on Form S-3 (No. 333-46545).

Editor's Note: CryoLife Customer Service may be accessed by telephone: 1-800-438-8285 (U.S. and Canada) 1-770-419-3355 (International) 1-770-590-3753 (International fax) E-mail: customerservice@cryolife.com

For additional information about the Company, visit CryoLife's web site: <http://www.cryolife.com>

--30--md/na*

CONTACT: CryoLife Inc., Atlanta
Roy Vogelanz, 800/438-8285

KEYWORD: GEORGIA
INDUSTRY KEYWORD: MEDICINE BIOTECHNOLOGY